ABSTRACT. Immunomodulating agents are being inves-elements that defend against bacterial invasion. Thus, therapeutic tigated for treatment of infection in newborn infants where strategies that augment host defenses in the neonate such as morbidity and mortality remain high despite the continued transfusion of PMN or i.v. Ig have begun to be examined (10-development of new antibiotics. We studied the effect of 18). The development of immunomodulating drugs that directly the methylxanthine pentoxifylline on polymorphonuclear stimulate PMN function is an alternative approach that may leukocyte (PMN) chemotaxis, F-actin content, and phag-offer advantages over PMN or i.v. Ig transfusion in regard to ocytic activity as measured by nitroblue tetrazolium reduc-specificity of effect, ease of administration, availability, and side tion and Hz02 production in neonates and adults to deter-effects (10). A number of agents that enhance PMN function mine whether pentoxifylline might be useful in augmenting have been investigated but none are in routine clinical use and PMN function. The drug was found to have a dose-depend-only a few, such as pentoxifylline, have been studied in newborn ent effect on both neonatal and adult PMN function with infants (8,(19)(20)(21)(22). enhancement at lower concentrations and suppression at Pentoxifylline is a methylxanthine that was introduced in 1984 higher concentrations. PMN chemotaxis increased 42% ( p for treatment of peripheral vasoocclusive disease. Sheetz, Wang, < 0.01) in neonates and 16% ( p < 0.05) in adults at 100 and Kreutzer were the first to demonstrate that pentoxifylline pg/mL of pentoxifylline and it decreased 4 and 25%, re-could enhance adult PMN motility in vitro (23). Subsequently, spectively, at 4000 wg/mL. PMN nitroblue tetrazolium we found that pentoxifylline decreased the morbidity and morreduction increased by 34% in neonates and 23% ( p < tality from experimentally induced Staphylococcus aureus infec-0.05) in adults at 100 wg/mL of pentoxifylline and de-tion in neonatal mice, due in part to enhancement of PMN creased by 52 (p < 0.01) and 74% ( p < 0.01), respectively, motility (19, 21). To begin to investigate the potential utility of at 2000 wg/mL. Similar dose-dependent responses were pentoxifylline in human neonates, Hill et al. (8) and Krause et noted with F-actin content and H202 production. These al. (22) evaluated the in vitro effects of this drug on neonatal and other observations support the hypothesis that pentox-PMN chemotaxis and noted enhancement of PMN motility. Our ifylline has a broad range of effects on PMN but that a study was designed to confirm and extend these findings to primary effect is alteration of PMN deformability. Pentox-include pentoxifylline effect on other PMN responses and to ifylline has potential clinical use as an immunomodulator further investigate the mechanism of action of pentoxifylline on in augmenting impaired PMN function in neonates and PMN function. The results indicate that pentoxifylline can enother immunocompromised hosts or in suppressing exces-hance or suppress PMN chemotaxis and phagocytic activity in sive PMN activity in certain disease processes. (Pediatr both neonates and adults depending on the dose and that its Res 29: 123-127,1991) effects appear to be mediated in part through alterations in PMN deformability. Abbreviations NBT, nitroblue tetrazolium MATERIALS AND METHODS
< 0.01) in neonates and 16% ( p < 0.05) in adults at 100 and Kreutzer were the first to demonstrate that pentoxifylline pg/mL of pentoxifylline and it decreased 4 and 25%, re-could enhance adult PMN motility in vitro (23) . Subsequently, spectively, at 4000 wg/mL. PMN nitroblue tetrazolium we found that pentoxifylline decreased the morbidity and morreduction increased by 34% in neonates and 23% ( p < tality from experimentally induced Staphylococcus aureus infec-0.05) in adults at 100 wg/mL of pentoxifylline and de-tion in neonatal mice, due in part to enhancement of PMN creased by 52 (p < 0.01) and 74% ( p < 0.01), respectively, motility (19, 21) . To begin to investigate the potential utility of at 2000 wg/mL. Similar dose-dependent responses were pentoxifylline in human neonates, Hill et al. (8) and Krause et noted with F-actin content and H202 production. These al. (22) evaluated the in vitro effects of this drug on neonatal and other observations support the hypothesis that pentox-PMN chemotaxis and noted enhancement of PMN motility. Our ifylline has a broad range of effects on PMN but that a study was designed to confirm and extend these findings to primary effect is alteration of PMN deformability. Pentox-include pentoxifylline effect on other PMN responses and to ifylline has potential clinical use as an immunomodulator further investigate the mechanism of action of pentoxifylline on in augmenting impaired PMN function in neonates and PMN function. The results indicate that pentoxifylline can enother immunocompromised hosts or in suppressing exces-hance or suppress PMN chemotaxis and phagocytic activity in sive PMN activity in certain disease processes. (Pediatr both neonates and adults depending on the dose and that its and 4000 pg/mL) for 10 min at 37°C before the chemotaxis 124 KRAUSE ET AL. assay. The pentoxifylline used in this assay and all other assays was a generous gift of Hoechst-Roussel Pharmaceuticals, Inc. (Somerville, NJ). It consisted of a powder preparation of the drug without additives. A standard liquid preparation was made by the addition of Medium 199 buffer to the powdered pentoxifylline. PMN chemotaxis was measured using a modified micropore filter assay (24). In brief, 5 x lo5 PMN10.7 mL were placed in the upper compartment of a modified Boyden chamber (Ahlco Corporation, Southington, CT) over cellulose nitrate filters with a diameter of 13 mm and a pore size of 5 pm (Sartorius Filters, Hayward, CA). Stabilized zymosan-activated normal serum (3 %) was placed in the lower compartment. The PMN were allowed to penetrate the filter during a 90-min incubation in a humid 5% C02 atmosphere at 37°C. The filters were removed, fixed, stained, clarified, and mounted on slides. An automated microsectioning counting technique was used to determine the number of PMN at 10-pm increments from 20 to 120 gm into the filter. Because we used a mixed leukocyte suspension, the first 20 pm of the filter were not examined to avoid inclusion of monocytes and lymphocytes in the cell counts. The mean distance migrated by the PMN in 90 min of incubation time, or LIZ0, was then determined. A mean LIZ0 value of triplicate determinations was calculated for each blood sample. PMN actin polymerization assay. Actin is a major protein component of the PMN cytoskeleton that plays a critical role in determining cell deformability, redistribution of cell surface receptors, and cell motility (25). The amount of actin can be measured in its condensed form (F-actin) using NBD phallacidin, a fluorescent probe that specifically binds F-actin. We used NBD phallacidin to determine the effect of pentoxifylline on the Factin content in neonatal and adult PMN. The effects of pentoxifylline on PMN actin was determined using a standard PMN actin polymerization assay (25). In brief, PMN were separated from whole blood with Hetastarch, washed in Hanks buffer, and standardized to 1.25 x lo6 cells/mL. PMN aliquots were then incubated either in Medium 199 buffer or lo-' f-methionylleucylphenylalanine for 10 min at 37°C followed by the addition of varying concentrations of pentoxifylline for 1 min in a gentle shaking water bath. The reaction was stopped by the addition of 37% formalin at 25°C for 15 min. The PMN were then added to a test tube that contained evaporated NBD phallacidin (25 pL/ tube) followed by incubation in 10 pL of ly~opho~phatidylcholine at 37°C for 10 min. The PMN were centrifuged at 150 x g for 5 min, resuspended in Hanks buffer, and immediately analyzed on the flow cytometer at a wavelength of 488 nm.
PMN phagocytosis (NBT) assay. The effect of pentoxifylline on PMN phagocytosis was determined using a NBT assay (26). In brief, PMN were separated from whole blood with Hetastarch, washed in Medium 199, and standardized to 5 x lo6 cells/mL. A total of 75 pL each of potassium cyanide and NBT were added to the PMN (300 pL). Aliquots of the PMN solutions were then mixed with either Medium 199 (control) or opsonized zymosan followed by incubation with various concentrations of pentoxifylline for 15 min at 37°C in a shaking water bath. The reaction was stopped with 1 N HCl, decanted, and pyridine was added. This mixture was placed in a boiling water bath for 15 min, centrifuged at 650 x g, and the supernatant placed in a glass cuvette for analysis in a spectrophotometer at 550 nm. The average of triplicate samples was obtained and the difference between zymosan and control samples determined. PMN H202 production. The effect of pentoxifylline on PMN H202 production was evaluated using a simple colorimetric assay (27) . PMN (4 x 106/mL) separated from whole blood by Ficoll Hypaque followed by dextran sedimentation were incubated in varying concentrations of pentoxifylline with phenol red, horseradish peroxidase, and either opsonized zymosan (0.5 mg/mL) or Hanks buffer in a 37°C water bath for 1 h. The PMN were then centrifuged and the supernatant removed. The supernatant was placed in a glass cuvette after the addition of 10 M NaOH. Spectrophotometric readings were taken at 6 18 nm. The amount of H202 produced was determined by comparing the absorbance of the PMN solution with a standard absorbance curve generated by varying concentrations of H202.
Statistical analysis. Statistical significance of differences between groups was performed using the two-tailed t test with Bonferroni correction (28) . RESULTS 
PMN chemotaxis.
Pentoxifylline caused a significant increase in neonatal and adult PMN chemotaxis at concentrations of 100 and 500 pg/mL as shown in Figure 1 . The percent change in PMN chemotaxis caused by pentoxifylline was significantly greater in neonates than in adults at 100 (42 versus 16%, p = 0.014) and 500 pg/mL (44 versus 30%, p < 0.01), indicating that the drug had a greater effect on PMN with impaired PMN chemotaxis. In separate experiments, pentoxifylline was found to inhibit adult (-25%, NS) and neonatal (-4%, NS) PMN chemotaxis at a concentration of 4000 pg/mL. Pentoxifylline was not found to be cytotoxic to PMN as demonstrated by trypan blue exclusion after incubation in 10,50, 100, 1000,2000, or 4000 pg/mL of pentoxifylline for 15 min at 37°C.
PMN F-actin polymerization. To help clarify the mechanism of pentoxifylline effect on PMN chemotaxis, neonatal and adult PMN were incubated in buffer or pentoxifylline and tested for F-actin content. In a time-response study, pentoxifylline (500 mg/mL) was found to maximally decrease F-actin after a 60-s exposure. Using this exposure time in PMN pretreated with fmethionylleucylphenylalanine, pentoxifylline was found to significantly decrease the amount of adult and neonatal PMN Factin in a dose-dependent manner as shown in Figure 2 . Pentoxifylline had no significant effect on the F-actin content of resting PMN.
PMN NBT reduction. The effect of pentoxifylline on adult PMN NBT reduction was similar to that on PMN chemotaxis with enhancement at lower concentrations (10-100 pg/mL) and impairment at higher concentrations (1000-2000 pg/mL) (Fig.  3) . Pentoxifylline significantly increased adult PMN NBT reduction at 10 and 100 Fg/mL ( p < 0.05 and p < 0.05) and significantly decreased it at 1000 and 2000 pg/mL ( p < 0.01 and p < 0.01). There was a similar pattern for neonatal PMN; Pentoxifylline C o n~e n t r a t i~n (ug/ml) (stippled bars) and eight adults (solid bars) was determined. Pentoxifylline enhanced PMN NBT reduction at lower concentrations (I0 and 100 pg/mL) and decreased it at higher concentrations (1000 and 2000 pg/ mL). Pentoxifylline significantly increased adult PMN NBT reduction at 10 pg/mL ( p < 0.01) and 100 pg/mL ( p < 0.05) and significantly decreased it at 1000 and 2000 pg/mL ( p < 0.01 for both). There was a similar pattern for neonatal PMN; however, only a decrease at 2000 pg/ mL was statistically significant ( p < 0.0 1). Asterisks indicate a statistically significant difference from control.
however, only the decrease at 2000 pg/mL was statistically significant ( p < 0.01).
PMN oxidative metabolism. To further clarify the mechanism of action of pentoxifylline on NBT reduction, we examined the effect of pentoxifylline on PMN H202 production when activated by zymosan. Although there was a similar pattern of pentoxifylline enhancement and impairment of H202 production as with chemotaxis and NBT production, the only significant effect was impairment of H202 production in adult PMN at pentoxifylline concentrations of 100 and 1000 pg/mL and in neonatal PMN at a pentoxifylline concentration of 1000 pg/mL (Fig. 4) . effect on blood viscosity was due to enhancement of erythrocyte flexibility (30) . In 1983, Sheetz, Wang, and Kreutzer presented data suggesting an additional explanation for the hemorheologic properties of the drug: destabilization of the cell membrane of the PMN (23). They also discovered that pentoxifylline could increase PMN motility, suggesting that the drug might be used as an immunomodulator. It was immediately apparent that newborn infants might benefit from pentoxifylline immunomodulation because they had impairment in PMN motility that was thought to contribute to their increased morbidity and mortality from infection (2). We therefore initiated a study of the effects of pentoxifylline on PMN function in newborn mice. The drug was found to enhance both in vitro PMN increased by the addition of pentoxifylline. We undertook the present study to determine whether pentoxifylline could enhance PMN phagocytosis and oxidative metabolism as well as chemotaxis in human newborns. The results demonstrate that pentoxifylline can either enhance or suppress PMN chemotaxis and phagocytic activity. In neonates, pentoxifylline enhanced PMN chemotaxis but not phagocytosis. In adults, pentoxifylline enhanced both PMN chemotaxis and phagocytosis. Because H202 production was not increased by pentoxifylline in adult PMN, enhancement of the NBT reaction of adult PMN may be due to increased engulfment of bacteria (zymosan) rather than increased oxidative metabolism.
The concentration of pentoxifylline required for enhancement of PMN chemotaxis in neonates and adults (250 pg/mL) is higher than concentrations of the drug achievable with current dosing guidelines in humans where 2 to 4 mg/kg of pentoxifylline given by the oral route to adults produces average peak drug concentrations of 0.5 to 1 pg/mL (3 1). The maximum reported dose of pentoxifylline administered to humans to date has been approximately 3 mg/kg given i.v. resulting in a peak blood concentration of 2.5 pg/mL (32). A similar dose in neonatal mice (5 mg/kg s.c.) has been shown to result in a similar peak pentoxifylline blood concentration (1 pg/mL) (2 1). Maderazo et al. (21) found that peak pentoxifylline blood concentrations of 250 pg/mL, noted to enhance PMN function in the present study, could be achieved in neonatal mice when given doses of
